

# EVIDENCE FOR 5FUC

## HISTOLOGIC CLASSIFICATION OF AK PRIOR TO 2018

1. J. Rowert-Huber, M.J.P., T. Forschner, C. Ulrich, J. Eberle, H. Kerl, W. Sterry, and E. Stockfleth, *Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification*. Br J Dermatol, 2007.

## EVIDENCE FOR LACK OF CORRELATION BETWEEN HISTOLOGIC GRADING, CLINICAL GRADE AND PROGRESSION TO SCC

2. Fernandez-Figueras, M.T., et al., *Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin*. J Eur Acad Dermatol Venereol, 2015. **29**(5): p. 991-7.
3. Schmitz, L., et al., *Actinic keratosis: correlation between clinical and histological classification systems*. J Eur Acad Dermatol Venereol, 2016. **30**(8): p. 1303-7.

## NEW CLINICAL SCORE-ACTINIC KERATOSIS AREA AND SEVERITY INDEX (AKASI)

4. Dirschka, T., et al., *A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index*. J Eur Acad Dermatol Venereol, 2017. **31**(8): p. 1295-1302.
5. Schmitz, L., et al., *Actinic keratosis area and severity index (AKASI) is associated with the incidence of squamous cell carcinoma*. J Eur Acad Dermatol Venereol, 2018. **32**(5): p. 752-756.

## NEW HISTOLOGICAL GRADING SYSTEM (PRO)

6. Schmitz, L., et al., *Actinic keratoses show variable histological basal growth patterns - a proposed classification adjustment*. J Eur Acad Dermatol Venereol, 2018. **32**(5): p. 745-751.
7. Schmitz, L., et al., *Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability*. J Eur Acad Dermatol Venereol, 2019. **33**(6): p. 1092-1097.
8. Schmitz, L., et al., *Cutaneous squamous cell carcinomas are associated with basal proliferating actinic keratoses*. Br J Dermatol, 2019. **180**(4): p. 916-921.
9. Welzel, J., *From actinic keratosis to squamous cell carcinoma - answers to some open questions*. Br J Dermatol, 2019. **180**(4): p. 699-700.

### **EVIDENCE FOR 5FU OVER OTHER FIELD THERAPIES**

10. Jansen, M.H.E., et al., *Randomized Trial of Four Treatment Approaches for Actinic Keratosis*. New England Journal of Medicine, 2019. **380**(10): p. 935-946.
11. Wehner, M.R., *Comparing the efficacy of field treatments for actinic keratosis: a critical appraisal of a randomized trial in the New England Journal of Medicine*. Br J Dermatol, 2020. **182**(6): p. 1343-1344.
12. Weinstock, M.A., et al., *Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial*. JAMA Dermatol, 2018. **154**(2): p. 167-174.

### **EVIDENCE FOR 5FUC AS AN ALTERNATIVE TO 5FU**

13. Cunningham, T.J., et al., *Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy*. J Clin Invest, 2017. **127**(1): p. 106-116.
14. Rosenberg, A.R., et al., *Skin cancer precursor immunotherapy for squamous cell carcinoma prevention*. JCI Insight, 2019. **4**(6).

### **OTHER STUDIES OF 5FUC**

15. Torezan, L., et al., *A randomized split-scalp study comparing calcipotriol-assisted methyl aminolaevulinate photodynamic therapy (MAL-PDT) with conventional MAL-PDT for the treatment of actinic keratosis*. Br J Dermatol, 2018. **179**(4): p. 829-835.
16. Molina, G.E., et al., *Topical Combination of Fluorouracil and Calcipotriene as a Palliative Therapy for Refractory Extramammary Paget Disease*. JAMA Dermatol, 2019.

### **ROLE OF CRYOSURGERY**

17. Heppt, M.V., et al., *Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis*. Br J Dermatol, 2019. **180**(4): p. 740-748.

### **THE FUTURE-MOLECULAR BASIS FOR AK EVOLVING INTO SCC**

18. Bakshi, A., et al., *The clinical course of actinic keratosis correlates with underlying molecular mechanisms*. Br J Dermatol, 2020. **182**(4): p. 995-1002.